PTP1B inhibition promotes microglial phagocytosis in Alzheimer's disease models by enhancing SYK signaling.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and mechanistic in vitro research with no human subjects
PubMed 41628337 · doi:10.1073/pnas.2521944123
What was done
The authors investigated the role of protein tyrosine phosphatase 1B (PTP1B) in microglial phagocytosis and Alzheimer's disease pathology. Using APP/PS1 transgenic mouse models and microglial assays, they tested the effects of genetic deletion and pharmacological inhibition of PTP1B on memory performance, amyloid beta (Aβ) burden, microglial transcription, phagocytic capacity, AKT-mTOR energy metabolism signaling, and SYK pathway interaction.
What was found
Genetic deletion or pharmacological inhibition of PTP1B ameliorated memory deficits and reduced Aβ burden in APP/PS1 mice. PTP1B deficiency shifted microglial transcription toward immune activation and enhanced phagocytosis and energy metabolism supported by AKT-mTOR signaling. SYK was identified as a direct substrate of PTP1B, and pharmacological inhibition of SYK established that PTP1B regulates microglial activation in a SYK-dependent manner. The abstract reports no quantitative values or sample sizes.
Why it matters
This study defines a mechanism linking PTP1B dephosphorylation of SYK to impaired microglial Aβ clearance, identifying PTP1B inhibition as a potential therapeutic target in Alzheimer's disease.
Limits
The study is entirely preclinical, relying on transgenic mouse models and in vitro assays with no human clinical validation. The abstract provides no sample sizes, effect sizes, variance measures, or p-values.
Cited by
- supports Microglial phagocytosis of proteins is impaired in individuals with Alzheimer's disease.